For example, previous trials of EGFR tyrosine kinase inhibitors (TKIs), such as INTEREST (Iressa NSCLC Trial Evaluating Response and Survival again Taxotere) and IPASS (Iressa Pan-Asia Study), have reported that sufficient biopsy samples were available in only 42% and 31%, respectively, of the patient subjects to allow a complete molecular diagnosis, and consequently that multiple tissue biopsies were required for a complete tumor characterization [9,10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.